Company news

Dyne Therapeutics, Inc. news in 2025

Dyne Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

December 22, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 10, 2025

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

December 8, 2025

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

December 7, 2025

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

December 7, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8: 00 a.m. ET

December 6, 2025

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 4, 2025

Dyne Therapeutics to Present at Upcoming Investor Conferences

November 2, 2025

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

October 5, 2025

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

October 1, 2025

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

September 28, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

August 3, 2025

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

July 27, 2025

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

July 1, 2025

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

June 29, 2025

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

June 29, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

June 16, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8: 00 a.m. ET

June 15, 2025

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

June 4, 2025

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

April 23, 2025

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

April 14, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 13, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

March 19, 2025

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

March 19, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

March 15, 2025

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

March 10, 2025

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 26, 2025

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

February 13, 2025

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 2, 2025

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

January 20, 2025

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYN...

January 9, 2025

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8: 00 a.m. ET

January 7, 2025

Decks in 2025